Celldex Therapeutics Stock Debt To Equity

CLDX Stock

USD 26.51 0.11 0.42%

Celldex Therapeutics fundamentals help investors to digest information that contributes to Celldex Therapeutics' financial success or failures. It also enables traders to predict the movement of Celldex Stock. The fundamental analysis module provides a way to measure Celldex Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Celldex Therapeutics stock.

Last Reported

Projected for Next Year

Debt To Equity is likely to drop to 0 in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Celldex Therapeutics Company Debt To Equity Analysis

Celldex Therapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.

D/E

Total Debt

Total Equity

More About Debt To Equity | All Equity Analysis

Current Celldex Therapeutics Debt To Equity

0.01 %

Most of Celldex Therapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Celldex Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Celldex Debt To Equity Driver Correlations

Understanding the fundamental principles of building solid financial models for Celldex Therapeutics is extremely important. It helps to project a fair market value of Celldex Stock properly, considering its historical fundamentals such as Debt To Equity. Since Celldex Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Celldex Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Celldex Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Net Receivables	Accounts Payable	Short Term Debt	Common Stock	Intangible Assets	Current Deferred Revenue	Property Plant Equipment	Short Term Investments	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Short Long Term Debt	Net Invested Capital	Long Term Investments	Net Working Capital	Capital Stock
Total Assets		0.98	-0.43	-0.67	0.33	0.94	0.36	0.73	0.03	0.39	0.19	0.54	0.44	0.88	0.84	-0.64	0.68	0.56	0.66	-0.53	0.67	0.61
Total Stockholder Equity	0.98		-0.43	-0.69	0.16	0.98	0.31	0.75	-0.07	0.27	0.03	0.5	0.32	0.93	0.91	-0.61	0.7	0.49	0.71	-0.57	0.74	0.69
Net Debt	-0.43	-0.43		-0.07	-0.09	-0.42	0.03	-0.23	0.13	-0.39	0.03	-0.55	-0.42	-0.15	-0.26	0.36	-0.04	0.09	-0.08	-0.03	0.02	0.07
Retained Earnings	-0.67	-0.69	-0.07		-0.06	-0.66	-0.6	-0.56	0.13	0.22	-0.08	0.06	0.11	-0.72	-0.66	0.64	-0.93	-0.76	-0.36	0.5	-0.64	-0.8
Total Liab	0.33	0.16	-0.09	-0.06		0.0	0.28	0.04	0.53	0.72	0.91	0.35	0.74	-0.05	-0.17	-0.31	0.11	0.48	-0.06	0.13	-0.19	-0.27
Total Current Assets	0.94	0.98	-0.42	-0.66	0.0		0.26	0.75	-0.17	0.16	-0.11	0.48	0.23	0.96	0.96	-0.55	0.66	0.38	0.73	-0.6	0.78	0.73
Net Receivables	0.36	0.31	0.03	-0.6	0.28	0.26		0.33	0.08	-0.02	0.29	-0.28	0.01	0.28	0.15	-0.4	0.45	0.67	-0.09	-0.55	0.09	0.23
Accounts Payable	0.73	0.75	-0.23	-0.56	0.04	0.75	0.33		-0.24	0.2	-0.06	0.34	0.21	0.74	0.68	-0.42	0.49	0.31	0.51	-0.68	0.53	0.56
Short Term Debt	0.03	-0.07	0.13	0.13	0.53	-0.17	0.08	-0.24		0.39	0.36	0.28	0.54	-0.19	-0.25	-0.02	-0.15	0.23	-0.03	0.16	-0.17	-0.3
Common Stock	0.39	0.27	-0.39	0.22	0.72	0.16	-0.02	0.2	0.39		0.45	0.68	0.79	0.05	0.01	-0.2	-0.14	0.22	0.15	0.04	-0.15	-0.31
Intangible Assets	0.19	0.03	0.03	-0.08	0.91	-0.11	0.29	-0.06	0.36	0.45		0.08	0.54	-0.13	-0.26	-0.22	0.08	0.37	-0.19	0.13	-0.24	-0.25
Current Deferred Revenue	0.54	0.5	-0.55	0.06	0.35	0.48	-0.28	0.34	0.28	0.68	0.08		0.81	0.33	0.39	-0.38	0.04	-0.01	0.3	0.04	0.09	-0.05
Property Plant Equipment	0.44	0.32	-0.42	0.11	0.74	0.23	0.01	0.21	0.54	0.79	0.54	0.81		0.09	0.07	-0.29	-0.05	0.12	0.07	0.13	-0.14	-0.27
Short Term Investments	0.88	0.93	-0.15	-0.72	-0.05	0.96	0.28	0.74	-0.19	0.05	-0.13	0.33	0.09		0.97	-0.47	0.7	0.42	0.79	-0.67	0.86	0.82
Net Tangible Assets	0.84	0.91	-0.26	-0.66	-0.17	0.96	0.15	0.68	-0.25	0.01	-0.26	0.39	0.07	0.97		-0.47	0.68	0.33	0.77	-0.54	0.85	0.8
Long Term Debt Total	-0.64	-0.61	0.36	0.64	-0.31	-0.55	-0.4	-0.42	-0.02	-0.2	-0.22	-0.38	-0.29	-0.47	-0.47		-0.66	-0.52	-0.14	0.16	-0.27	-0.34
Capital Surpluse	0.68	0.7	-0.04	-0.93	0.11	0.66	0.45	0.49	-0.15	-0.14	0.08	0.04	-0.05	0.7	0.68	-0.66		0.72	0.48	-0.25	0.73	0.8
Short Long Term Debt	0.56	0.49	0.09	-0.76	0.48	0.38	0.67	0.31	0.23	0.22	0.37	-0.01	0.12	0.42	0.33	-0.52	0.72		0.17	-0.31	0.32	0.41
Net Invested Capital	0.66	0.71	-0.08	-0.36	-0.06	0.73	-0.09	0.51	-0.03	0.15	-0.19	0.3	0.07	0.79	0.77	-0.14	0.48	0.17		-0.36	0.92	0.73
Long Term Investments	-0.53	-0.57	-0.03	0.5	0.13	-0.6	-0.55	-0.68	0.16	0.04	0.13	0.04	0.13	-0.67	-0.54	0.16	-0.25	-0.31	-0.36		-0.42	-0.5
Net Working Capital	0.67	0.74	0.02	-0.64	-0.19	0.78	0.09	0.53	-0.17	-0.15	-0.24	0.09	-0.14	0.86	0.85	-0.27	0.73	0.32	0.92	-0.42		0.92
Capital Stock	0.61	0.69	0.07	-0.8	-0.27	0.73	0.23	0.56	-0.3	-0.31	-0.25	-0.05	-0.27	0.82	0.8	-0.34	0.8	0.41	0.73	-0.5	0.92

Click cells to compare fundamentals

Celldex Debt To Equity Historical Pattern

Today, most investors in Celldex Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Celldex Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's debt to equity growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Celldex Therapeutics debt to equity as a starting point in their analysis.

Celldex Therapeutics Debt To Equity

Timeline

High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.

Competition

Predict Celldex Therapeutics

Debt To Equity Over Time

Celldex Total Stockholder Equity

Total Stockholder Equity

450.63 Million

At this time, Celldex Therapeutics' Total Stockholder Equity is fairly stable compared to the past year.

According to the company disclosure, Celldex Therapeutics has a Debt To Equity of 0.011%. This is 99.98% lower than that of the Biotechnology sector and 99.94% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.98% higher than that of the company.

Celldex Debt To Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Celldex Therapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Celldex Therapeutics could also be used in its relative valuation, which is a method of valuing Celldex Therapeutics by comparing valuation metrics of similar companies.

Celldex Therapeutics is currently under evaluation in debt to equity category among its peers.

Celldex Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Celldex Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Celldex Therapeutics' managers, analysts, and investors.

Environmental

Governance

Social

Celldex Fundamentals

	Return On Equity	-0.3
	Return On Asset	-0.2
	Operating Margin	(16.34) %
	Current Valuation	998.58 M
	Shares Outstanding	66.34 M
	Shares Owned By Institutions	100.00 %
	Number Of Shares Shorted	7.83 M
	Price To Earning	(2.21) X
	Price To Book	2.23 X
	Price To Sales	176.30 X
	Revenue	6.88 M
	Gross Profit	(79.9 M)
	EBITDA	(139.03 M)
	Net Income	(141.43 M)
	Cash And Equivalents	356.82 M
	Cash Per Share	7.63 X
	Total Debt	2.54 M
	Debt To Equity	0.01 %
	Current Ratio	12.29 X
	Book Value Per Share	11.85 X
	Cash Flow From Operations	(107.29 M)
	Short Ratio	7.53 X
	Earnings Per Share	(2.58) X
	Target Price	67.1
	Number Of Employees	160
	Beta	1.59
	Market Capitalization	1.76 B
	Total Asset	465.63 M
	Retained Earnings	(1.4 B)
	Working Capital	400.57 M
	Current Asset	294.94 M
	Current Liabilities	30.24 M
	Net Asset	465.63 M

About Celldex Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Celldex Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Celldex Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Celldex Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC